KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Gross Margin (2016 - 2025)

Fulgent Genetics' Gross Margin history spans 11 years, with the latest figure at 39.1% for Q4 2025.

  • For Q4 2025, Gross Margin fell 269.0% year-over-year to 39.1%; the TTM value through Dec 2025 reached 40.56%, up 274.0%, while the annual FY2025 figure was 40.56%, 274.0% up from the prior year.
  • Gross Margin for Q4 2025 was 39.1% at Fulgent Genetics, down from 42.24% in the prior quarter.
  • Across five years, Gross Margin topped out at 80.92% in Q3 2021 and bottomed at 19.18% in Q4 2022.
  • The 5-year median for Gross Margin is 41.94% (2024), against an average of 47.86%.
  • The largest annual shift saw Gross Margin soared 3172bps in 2021 before it tumbled -5613bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 75.31% in 2021, then crashed by -75bps to 19.18% in 2022, then skyrocketed by 87bps to 35.78% in 2023, then grew by 17bps to 41.79% in 2024, then dropped by -6bps to 39.1% in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Gross Margin are 39.1% (Q4 2025), 42.24% (Q3 2025), and 42.1% (Q2 2025).